Premium
Expression analysis of δ‐catenin and prostate‐specific membrane antigen: Their potential as diagnostic markers for prostate cancer
Author(s) -
Burger Michelle Jane,
Tebay Michelle Anne,
Keith Patricia Anne,
Samaratunga Hema Mali,
Clements Judith,
Lavin Martin Francis,
Gardiner Robert Alexander
Publication year - 2002
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.10468
Subject(s) - prostate cancer , pca3 , prostate , glutamate carboxypeptidase ii , medicine , prostate specific antigen , hyperplasia , cancer , management of prostate cancer , pathology , cancer research
The current approach to prostate cancer diagnosis has major limitations including the inability of prostate‐specific antigen (PSA) assays to accurately differentiate between prostate cancer and benign prostate hyperplasia (BPH) and the imprecision of transrectal ultrasound (TRUS) biopsy sampling. We have employed cDNA microarray screening to compare gene expression patterns in BPH and tumour samples to identify expression markers that may be useful in discriminating between these conditions. Screening of 3 individual cDNA arrays identified 8 genes with expression 3‐fold greater in 6 tumour tissues than in 1 nontumour sample and 1 BPH sample. Real‐time PCR was used to confirm the overexpression of these 8 genes and 12 genes selected from the literature against a panel of 17 tumours and 11 BPH samples. Two genes, δ‐catenin (delta‐catenin; CTNND2 ) and prostate‐specific membrane antigen (PSMA; FOLH1 ), were significantly overexpressed in prostate cancer compared to BPH. Prostate epithelial cells stained positively for δ‐catenin and PSMA in our prostate cancer tissues, whereas the majority of our BPH tissues were negative for both markers. Thus we have identified δ‐catenin (not previously associated with prostatic adenocarcinoma) and confirmed the potential of PSMA as potential candidates for the diagnosis and management of prostate cancer. © 2002 Wiley‐Liss, Inc.